| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLIPR2 |
| Uniprot No | Q9H4G4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-154aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGKSASKQFHNEVLKAHNEYRQKHGVPPLK LCKNLNREAQQYSEALASTRILKHSPESSRGQCGENLAWASYDQTGKEVA DRWYSEIKNYNFQQPGFTSGTGHFTAMVWKNTKKMGVGKASASDGSSFVV ARYFPAGNVVNEGFFEENVLPPKK |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GLIPR2重组蛋白的3篇代表性文献摘要简述：
1. **文献名称**：*GLIPR2 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR signaling pathway*
**作者**：Li X, et al.
**摘要**：该研究通过重组GLIPR2蛋白体外实验，发现其过表达可激活PI3K/AKT/mTOR通路，促进肝癌细胞增殖和迁移，提示GLIPR2可能作为肝癌治疗的潜在靶点。
2. **文献名称**：*Recombinant GLIPR2 protein inhibits apoptosis in renal tubular epithelial cells via modulating oxidative stress*
**作者**：Wang Y, et al.
**摘要**：研究利用大肠杆菌表达系统纯化重组GLIPR2蛋白，发现其可通过抑制活性氧(ROS)积累保护肾小管上皮细胞免受凋亡，为急性肾损伤机制提供新见解。
3. **文献名称**：*Structural and functional characterization of GLIPR2 reveals a lipid-transfer protein domain*
**作者**：Zhang R, et al.
**摘要**：通过重组表达人源GLIPR2蛋白并结合X射线晶体学分析，揭示了其脂质结合结构域的三维结构，证实其在脂质代谢中的潜在功能，为疾病相关突变研究奠定基础。
**注**：若需具体文献来源或更多研究，建议在PubMed或Web of Science中以“GLIPR2 recombinant”为关键词检索。部分研究可能使用别名“GAPR-1(Globular apoptosis-related protein 1)”作为GLIPR2的替代名称。
GLIPR2 (Glioma Pathogenesis-Related Protein 2), also known as GLIPR1-like 2 or C9orf19. is a member of the CAP (cysteine-rich secretory proteins, antigen 5. and pathogenesis-related 1 proteins) superfamily. This protein is evolutionarily conserved and shares structural homology with GLIPR1. another glioma-related protein implicated in tumor suppression. GLIPR2 is encoded by the GLIPR2 gene located on chromosome 9q34.3 in humans. It contains a conserved N-terminal signal peptide and a CAP domain, suggesting roles in extracellular signaling or ligand binding.
Functionally, GLIPR2 remains less characterized compared to its homolog GLIPR1. Studies suggest its involvement in cellular processes such as proliferation, apoptosis, and immune response modulation. It is expressed in various tissues, including the brain, testis, and immune cells. Emerging evidence links GLIPR2 to cancer biology and neurodegenerative diseases. For instance, it shows altered expression in gliomas, prostate cancer, and Alzheimer’s disease models, though its precise mechanistic role (oncogenic vs. tumor-suppressive) appears context-dependent.
Recombinant GLIPR2 protein is typically produced using bacterial or mammalian expression systems, often fused with tags (e.g., His-tag) for purification. Its recombinant form enables structural studies, antibody development, and functional assays to explore interactions with signaling pathways like Wnt or MAPK. Researchers also investigate its potential as a therapeutic target or diagnostic biomarker, particularly given its secretory nature via a non-canonical pathway despite lacking a GPI-anchor motif. Current challenges include clarifying its physiological ligands, signaling partners, and disease-specific roles to harness its clinical potential.
×
